GLP-1 Side Effects: Complete Guide to Ozempic, Wegovy, Mounjaro and Other GLP-1 Medicines
GLP-1 receptor agonists, semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), share a common side-effect profile dominated by gastrointestinal symptoms. They also share a boxed warning for thyroid C-cell tumours and serious labelled risks for pancreatitis, kidney injury, gallbladder disease, and hypoglycaemia with insulin or sulfonylureas.
The most common GLP-1 side effects are gastrointestinal, nausea, vomiting, diarrhoea, constipation, abdominal pain, usually worst during dose escalation. The most serious labelled risks are pancreatitis, acute kidney injury, gallbladder disease, severe hypoglycaemia with insulin/sulfonylureas, and the boxed warning for thyroid C-cell tumours.
Key Takeaways
- All GLP-1 receptor agonists carry an FDA boxed warning for thyroid C-cell tumours.
- The most common side effects across the class are gastrointestinal, nausea, vomiting, diarrhoea, constipation, abdominal pain.
- Serious labelled risks: pancreatitis, acute kidney injury, gallbladder disease, hypoglycaemia with insulin/sulfonylureas, diabetic retinopathy worsening, hypersensitivity.
- Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist with greater weight-loss efficacy and similar safety profile.
- GLP-1 medicines slow gastric emptying, disclose use to your anaesthetist before any procedure (aspiration risk).
- Check any GLP-1 medicine against your full medication list with the Allmeds drug interaction checker.
What are GLP-1 medicines, and how do they work?
GLP-1 receptor agonists mimic glucagon-like peptide-1, a gut hormone released after meals. They stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. Tirzepatide additionally activates the GIP receptor, producing greater weight loss.
| Generic | Brand names | Indication | Route |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | T2D · weight management · CV risk | Weekly injection / daily oral |
| Tirzepatide | Mounjaro, Zepbound | T2D · weight management | Weekly injection |
| Liraglutide | Victoza, Saxenda | T2D · weight management | Daily injection |
| Dulaglutide | Trulicity | T2D · CV risk | Weekly injection |
| Exenatide | Byetta, Bydureon | T2D | Twice-daily or weekly injection |
| Retatrutide | (investigational) | Obesity, T2D (in trials) | Weekly injection (trial setting) |
What side effects do all GLP-1 medicines share?
The table below summarises labelled side effects across the GLP-1 class. Severity colour-coding follows FDA prescribing information: red = serious / boxed-warning class, amber = common but generally manageable, grey = monitoring required.
| Side Effect | What May Occur | Why It Matters |
|---|---|---|
| Pancreatitis | Severe, persistent abdominal pain radiating to the back, nausea, vomiting | All GLP-1 labels warn about acute pancreatitis. Stop and seek urgent assessment. |
| Thyroid C-cell tumours (boxed warning) | Neck mass, hoarseness, dysphagia, persistent neck pain | Animal studies show medullary thyroid carcinoma risk. Contraindicated with MTC/MEN2 history. |
| Acute kidney injury | Reduced urine output, swelling, usually after vomiting or diarrhoea | Dehydration from GI side effects can precipitate AKI. |
| Severe hypoglycaemia | Sweating, shakiness, confusion, palpitations, seizure | Risk rises sharply with insulin or sulfonylureas. Dose reduction usually required. |
| Gallbladder disease | Right-upper abdominal pain, fever, jaundice | Cholelithiasis and cholecystitis reported, especially with rapid weight loss. |
| Severe GI reactions | Persistent nausea, vomiting, diarrhoea, constipation, abdominal pain | Common and dose-dependent. Most pronounced at initiation and escalation. |
| Diabetic retinopathy worsening | Blurred vision, vision changes | Rapid glucose lowering has been associated with transient worsening. |
| Hypersensitivity | Rash, urticaria, angioedema, anaphylaxis | Stop and seek urgent care for serious allergic features. |
| Aspiration risk during anaesthesia | Food retained in stomach during sedation | Disclose GLP-1 use to your anaesthetist before any procedure. |
Taking a GLP-1 medicine alongside other medications?
Check it against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
How do GLP-1 side effects compare between medicines?
All GLP-1 medicines share the same major warnings, but specific side-effect frequencies and additional warnings differ. See the drug-specific pages below for the full FDA-labelled profile.
What drug interactions matter for GLP-1 medicines?
The most clinically relevant interactions involve hypoglycaemia risk, oral drug absorption, and contraceptive efficacy. See drug-pair pages for detail:
Common Questions About GLP-1 Side Effects
Gastrointestinal symptoms dominate the side-effect profile: nausea, vomiting, diarrhoea, constipation, and abdominal pain. These are usually worst during initiation and dose escalation and improve with continued use. Other common side effects include decreased appetite, fatigue, and headache.
Yes, Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, and Saxenda all carry an FDA boxed warning for thyroid C-cell tumours based on rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Yes, acute pancreatitis is a labelled risk for all GLP-1 receptor agonists. Stop the medicine and seek urgent assessment for severe, persistent abdominal pain that may radiate to the back, particularly when accompanied by vomiting.
Discuss with your prescriber and anaesthetist. GLP-1 medicines slow gastric emptying, which can leave food in the stomach during sedation or general anaesthesia and increase aspiration risk. Many anaesthetic services now pause GLP-1 medicines before elective procedures.
Alcohol is not a direct contraindication but compounds GI side effects (nausea, dehydration) and hypoglycaemia risk if you are also taking insulin or sulfonylureas. Drink less during initiation and dose escalation, avoid drinking on an empty stomach, and maintain hydration.
References
- U.S. Food & Drug Administration. Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, current prescribing information. accessdata.fda.gov.
- European Medicines Agency. Ozempic, Wegovy, Mounjaro EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
Check any GLP-1 medicine against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.